Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer
While several molecular targets have been identified for adenocarcinoma (ACA) of the lung, similar drivers with squamous cell carcinoma (SCC) are sparse. We compared signaling pathways and potential therapeutic targets in lung SCC and ACA tumors using reverse phase proteomic arrays (RPPA) from two independent cohorts of resected early stage NSCLC patients: a testing set using an MDACC cohort (N=140) and a validation set using the Cancer Genome Atlas (TCGA) cohorts. We identified multiple potentially targetable proteins upregulated in SCC, including NRF2, Keap1, PARP, TrkB, and Chk2. Of these potential targets, we found that TrkB also had significant increases in gene expression in SCC as compared to adenocarcinoma. Thus, we next validated the upregulation of TrkB both in vitro and in vivo and found that it was constitutively expressed at high levels in a subset of SCC cell lines. Furthermore, we found that TrkB inhibition suppressed tumor growth, invasiveness and sensitized SCC cells to tyrosine kinase EGFR inhibition in a cell-specific manner.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Oncotarget - 9(2018), 18 vom: 06. März, Seite 14268-14284 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gomez, Daniel Richard [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Revised 05.11.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.18632/oncotarget.24361 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM282370919 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM282370919 | ||
| 003 | DE-627 | ||
| 005 | 20231225033757.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18632/oncotarget.24361 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0941.xml |
| 035 | |a (DE-627)NLM282370919 | ||
| 035 | |a (NLM)29581842 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gomez, Daniel Richard |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.11.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a While several molecular targets have been identified for adenocarcinoma (ACA) of the lung, similar drivers with squamous cell carcinoma (SCC) are sparse. We compared signaling pathways and potential therapeutic targets in lung SCC and ACA tumors using reverse phase proteomic arrays (RPPA) from two independent cohorts of resected early stage NSCLC patients: a testing set using an MDACC cohort (N=140) and a validation set using the Cancer Genome Atlas (TCGA) cohorts. We identified multiple potentially targetable proteins upregulated in SCC, including NRF2, Keap1, PARP, TrkB, and Chk2. Of these potential targets, we found that TrkB also had significant increases in gene expression in SCC as compared to adenocarcinoma. Thus, we next validated the upregulation of TrkB both in vitro and in vivo and found that it was constitutively expressed at high levels in a subset of SCC cell lines. Furthermore, we found that TrkB inhibition suppressed tumor growth, invasiveness and sensitized SCC cells to tyrosine kinase EGFR inhibition in a cell-specific manner | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a TrkB | |
| 650 | 4 | |a lung cancer | |
| 650 | 4 | |a proteomics | |
| 650 | 4 | |a squamous cell carcinoma | |
| 700 | 1 | |a Byers, Lauren Averett |e verfasserin |4 aut | |
| 700 | 1 | |a Nilsson, Monique |e verfasserin |4 aut | |
| 700 | 1 | |a Diao, Lixia |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Lerong |e verfasserin |4 aut | |
| 700 | 1 | |a Tong, Pan |e verfasserin |4 aut | |
| 700 | 1 | |a Hofstad, Mia |e verfasserin |4 aut | |
| 700 | 1 | |a Saigal, Babita |e verfasserin |4 aut | |
| 700 | 1 | |a Wistuba, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Kalhor, Neda |e verfasserin |4 aut | |
| 700 | 1 | |a Swisher, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Youhong |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Waun Ki |e verfasserin |4 aut | |
| 700 | 1 | |a Suraokar, Milind |e verfasserin |4 aut | |
| 700 | 1 | |a Behrens, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Moran, Cesar |e verfasserin |4 aut | |
| 700 | 1 | |a Heymach, John Victor |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncotarget |d 2010 |g 9(2018), 18 vom: 06. März, Seite 14268-14284 |w (DE-627)NLM199620113 |x 1949-2553 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2018 |g number:18 |g day:06 |g month:03 |g pages:14268-14284 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18632/oncotarget.24361 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2018 |e 18 |b 06 |c 03 |h 14268-14284 | ||